# Neogenomics (NEO) — Earnings

NEO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/neo/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.05 |
| EPS estimate | $0.03 |
| EPS surprise | +49.25% |
| Revenue surprise | +2.40% |
| Revenue | $201.7M |
| Revenue estimate | $196.9M |
| Reported | Jul 28, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1077183/000107718326000059/neo-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/eac048cc-4405-59fd-06de-93608c393942.html) |

NeoGenomics reported Q2 2026 results on July 28, 2026. Earnings per share were $0.05, ahead of the $0.03 estimate by 49.25%. Revenue of $201.7 million beat the $196.9 million consensus by 2.40% and was the first quarter above $200 million in the table. Compared with Q2 2025, EPS rose from $0.03 and revenue rose about 11% from $181.3 million.

Annual EPS was a loss of $0.56 per share in 2022 and of $0.11 in 2023, then a profit of $0.10 in 2024 and $0.12 in 2025. The last loss in the table was Q1 2024, at $0.02 per share. Revenue rose every year, from $509.8 million in 2022 to $727.3 million in 2025, up about 43%. The first half of 2026 adds up to $0.06 per share on $388.4 million in revenue, against $0.03 on $349.3 million a year earlier. NeoGenomics' surprise was positive in all 20 quarters shown.

Q3 results came out between October 28 and November 8 in each of the past five years. That points to late October or early November 2026 for the next report, which will show whether revenue stays above $200 million.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 28, 2026 | $0.03 | $0.05 | 49.25% | $196.9M | $201.7M |
| Q1 2026 | Apr 28, 2026 | $0.01 | $0.01 | 72.41% | $184.5M | $186.7M |
| Q4 2025 | Feb 17, 2026 | $0.04 | $0.06 | 47.78% | $188.6M | $190.2M |
| Q3 2025 | Oct 28, 2025 | $0.02 | $0.03 | 46.34% | $183.7M | $187.8M |
| Q2 2025 | Jul 29, 2025 | $0.02 | $0.03 | 29.31% | $182.7M | $181.3M |
| Q1 2025 | Apr 29, 2025 | −$0.01 | $0.00 | 100.00% | $170.6M | $168.0M |
| Q4 2024 | Feb 18, 2025 | $0.03 | $0.04 | 38.89% | $173.2M | $172.0M |
| Q3 2024 | Nov 5, 2024 | $0.01 | $0.05 | 306.50% | $167.0M | $167.8M |
| Q2 2024 | Jul 29, 2024 | −$0.00 | $0.03 | 1067.74% | $161.8M | $164.5M |
| Q1 2024 | Apr 30, 2024 | −$0.04 | −$0.02 | 49.62% | $149.8M | $156.2M |
| Q4 2023 | Feb 20, 2024 | −$0.02 | $0.03 | 221.46% | $152.5M | $155.6M |
| Q3 2023 | Nov 6, 2023 | −$0.07 | $0.00 | 100.00% | $141.7M | $152.0M |
| Q2 2023 | Aug 8, 2023 | −$0.11 | −$0.05 | 56.18% | $137.4M | $146.9M |
| Q1 2023 | May 8, 2023 | −$0.14 | −$0.09 | 35.44% | $129.3M | $137.2M |
| Q4 2022 | Feb 23, 2023 | −$0.16 | −$0.06 | 63.55% | $130.0M | $138.7M |
| Q3 2022 | Nov 8, 2022 | −$0.21 | −$0.14 | 32.10% | $121.5M | $128.8M |
| Q2 2022 | Aug 9, 2022 | −$0.23 | −$0.16 | 31.77% | $122.9M | $125.1M |
| Q1 2022 | Apr 27, 2022 | −$0.24 | −$0.20 | 15.82% | $116.7M | $117.2M |
| Q4 2021 | Feb 23, 2022 | −$0.15 | −$0.14 | 7.22% | $125.7M | $125.7M |
| Q3 2021 | Nov 4, 2021 | −$0.09 | −$0.08 | 11.11% | $124.6M | $121.3M |

## Frequently Asked Questions

### When did Neogenomics (NEO) last report earnings?

Neogenomics last reported on Jul 28, 2026, covering fiscal Q2 2026.

### Did NEO beat earnings estimates?

Yes. Neogenomics reported EPS of $0.05 for Q2 2026 against a $0.03 estimate — a 49.25% beat.

### How much revenue did NEO report last quarter?

Neogenomics reported $201.7M in revenue for Q2 2026, against a consensus estimate of $196.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).